- Home
- RLAY vs ESNT Comparison
RLAY vs ESNT Comparison
Compare RLAY & ESNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RLAY | ESNT |
|---|---|---|
| Founded | 2015 | 2008 |
| Country | United States | Bermuda |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 5.9B |
| IPO Year | 2020 | 2013 |
Fundamental Metrics
Financial Performance| Metric | RLAY | ESNT |
|---|---|---|
| Price | $8.29 | $65.83 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 5 |
| Target Price | $16.00 | ★ $68.00 |
| AVG Volume (30 Days) | ★ 2.2M | 659.8K |
| Earning Date | 11-06-2025 | 02-13-2026 |
| Dividend Yield | N/A | ★ 1.88% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 6.87 |
| Revenue | $8,355,000.00 | ★ $1,263,558,000.00 |
| Revenue This Year | $20.47 | $3.87 |
| Revenue Next Year | N/A | $1.55 |
| P/E Ratio | ★ N/A | $9.58 |
| Revenue Growth | N/A | ★ 2.04 |
| 52 Week Low | $1.78 | $51.61 |
| 52 Week High | $9.04 | $67.09 |
Technical Indicators
Market Signals| Indicator | RLAY | ESNT |
|---|---|---|
| Relative Strength Index (RSI) | 57.67 | 65.68 |
| Support Level | $8.13 | $65.50 |
| Resistance Level | $8.76 | $67.09 |
| Average True Range (ATR) | 0.48 | 1.04 |
| MACD | -0.01 | 0.07 |
| Stochastic Oscillator | 54.63 | 77.82 |
Price Performance
Historical ComparisonAbout RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
About ESNT Essent Group Ltd.
Essent Group Ltd serves the housing finance industry by providing private mortgage insurance, reinsurance, risk management products, title insurance, and settlement services to mortgage lenders, borrowers, and investors to support homeownership. It provides credit protection to lenders and mortgage investors by covering a portion of the unpaid principal balance of a mortgage and certain related expenses in the event of a default. By providing capital to mitigate mortgage credit risk, the company allows lenders to make additional mortgage financing available to prospective homeowners.